12:00 AM
May 19, 2016
 |  BC Innovations  |  Emerging Company Profile

Mining for functionality

HiFiBiO's single cell-based platform discovers diverse, functional antibodies
HiFiBiO S.A.S.

Conventional antibody discovery platforms generate a small number of candidates that block a target, and even fewer that can alter the function of target cells. HiFiBiO S.A.S. has a platform that improves the odds of finding a viable therapeutic by rapidly producing large, genetically diverse sets of functional antibodies.

Standard platforms like phage display and hybridoma-based systems select antibodies based primarily on their ability to bind the target antigen. "So if you're looking for antibodies that make a functional change in a target cell, these platforms alone aren't sufficient," Chief Commercial Officer Colin Brenan told BioCentury.

HiFiBiO's platform - dubbed CelliGo - analyzes the full repertoire of B cells that a person or animal generates in response to an antigen, using single cell-microfluidics and a high throughput screening system, and screens the antibodies they produce for functional activity."By starting with the whole B cell repertoire then looking for antibody cohorts that are functional with high diversity, we offer...

Read the full 776 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >